Vilerm Cream

Acyclovir.

Each 100 g contains Acyclovir (INN: Aciclovir) 5 g.

Pharmacology: Pharmacodynamics: Acyclovir is an antiviral agent which is highly active in vitro against Herpes simplex virus (HSV) type I and II and Varicella zoster virus. Toxicity to mammalian host cells is low.
Acyclovir is phosphorylated after entry into herpes infected cells to the active compound acyclovir triphosphate. The first step in the process is dependent on the presence of the HSV coded thymidine kinase. Acyclovir triphosphate acts as an inhibitor of and substrate for the herpes specified DNA polymerase preventing further viral DNA synthesis with affecting normal cellular processes.
Pharmacokinetics: Percutaneous absorption of Acyclovir appears to be minimal following topical application of the drug to intact skin. The distribution of Acyclovir following topical application has not been determined. In vitro Acyclovir appears to be preferentially distributed into cells that are infected with herpesviruses. In vitro Acyclovir is metabolized in cells infected with herpesviruses, principally by intracellular phosphorylation of the drug by virus-coded thymidine kinase and several cellular enzymes. Following systemic absorption, Acyclovir is excreted principally in urine 0.04% of the daily dose.

For the treatment of herpes simplex virus infections of the skin initial and recurrent genital herpes and herpes labialis.

Apply to the lesion or impending lesions five times daily at approximately four-hourly intervals, as early as possible after the start of an infection. It is particularly important to start treatment of recurrent episodes during the prodromal period or when the lesions first appear. Treatment should be continued for 5 days.

Overdose and Treatment: No untoward effects would be expected if the entire contents Acyclovir 500 mg were ingested orally.
Acyclovir is dialyzable by hemodialysis.

Hypersensitivity or chemical intolerance to the components of the formulation.

For cutaneous use only. Do not apply to eye or inside the mouth or nose, or to any mucous membranes.

Pregnancy: Acyclovir has not been shown to be teratogenic in standard test following administration in animals. However, there are no adequate and controlled studies to date using Acyclovir in pregnant women, and the drug should be used during pregnancy only when the potential benefits justify the possible risks to the fetus.
Lactation: Although it is not known whether Acyclovir is distributed into milk following topical application. Therefore, Acyclovir cream should be used with caution in nursing women. Women who have active herpetic lesions near or on the breast should avoid nursing.

Transient burning or stinging, erythema or mild drying and flaking of skin have been reported in a small proportion of patients.

Acyclovir is not known to interact with any other drug.

Store in a dry place and below 30°C.

Topical Antivirals

D06BB03 - aciclovir ; Belongs to the class of topical antivirals used in the treatment of dermatological diseases.

E-D